Economic evaluation of folic acid food fortification in the Netherlands

European Journal of Public Health

Volumn 18, Issue 3, 2008, Pages 270-274

  Jentink, Janneke ^a   Van De Vrie Hoekstra, Nienke W ^a   De Jong Van Den Berg, Lolkje T W ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness analysis; Folic acid; Fortified food; Health care costs; Neural tube defects

Indexed keywords

FOLIC ACID;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; ECONOMICS; EXPERT SYSTEM; HEALTH CARE COST; LIFE EXPECTANCY; NETHERLANDS; NEURAL TUBE DEFECT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; FOOD, FORTIFIED; HUMANS; NETHERLANDS; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL NUTRITION PHYSIOLOGY; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS;

EID: 44649198686     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckm129     Document Type: Article

References (39)

1. Eichholzer M, Tönz O, Zimmermann R. Folic acid: a public-health challenge. Lancet 2006;367:1352-61.
2. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
3. Gezondheidsraad. Risico's van foliumzuurverrijking (Health council. Risks of fortification with folic acid). Den Haag: Gezondheidsraad, 2000; publication number 2000/21 (in Dutch).
4. Cornel MC, De Smit DJ, De Jong-van den Berg LTW. Folic acid-the scientific debate as a base for public health policy. Reprod Toxicol 2005;20:411-5.
5. Choumankovitch SF, Selhub J, Wilson PJF, et al. Folic acid intake from fortification in United States exceeds predictions. Nutr Epidemiol 2002;132:2792-8.
6. Mersereau P, Kilker K, Carter H, et al. Spina bifida and anencephaly before and after folic acid mandate - United States, 1995-1996 and 1999-2000 CDC. Morb Mortal Wkly Rep 2004;53:362-5.
7. Ray JG. Folic acid food fortification in Canada. Nutr Rev 2004;62(6,II):S35-9.
8. De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007;357:135-42.
9. De Walle HEK, De Jong- van den Berg LTW. Preconceptioneel foliumzuur: wie zijn de doelgroepen? (Preconceptional folic acid: who are the target groups?). EUROCAT lecture: Groningen, 2006 (in Dutch).
10. Meijer WM, De Walle HEK. Verschillen in foliumzuurbeleid en prevalentie van neuralebuisdefecten in Europa; aanbevelingen voor voedselverrijking in een EUROCAT-rapport (Differences in folic acid policy and prevalence of Neural tube defects in Europe; recommendations for enrichments in an EUROCAT report). Nederlands Tijdschrift voor Geneeskunde 2005;149:2561-4.
11. De Walle HEK, De Jong- van den Berg LTW. 10 years after the Dutch Folic Acid Campaign: the continuing challenge. Eur J Clin Pharmacol 2008 (in press).
12. Kelly AE, Haddix AC, Scanlon KS, et al. Cost-effectiveness of strategies to prevent neural tube defects. In: Gold MR, Siegel JE, Russel LB, Weinstien MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996: 313-48.
13. Central bureau for Statistics, Voorburg, 2006, (http://statline.cbs.nl/ StatWeb)(20 October 2006, date accessed).
14. Staal-Schreinemachers AL, Vos-Niël JME, Begeer JH. Toekomstperspectieven voor kinderen met spina bifida aperta (Future perspectives for children with spina bifida aperta). Nederlands Tijdschrift voor Geneeskunde 1996;140:1268-72.
15. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kosten-onderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg (geactualiseerde versie 2004) (Guideline for cost research, methods and prices for economic evaluations in health care). College voor zorgverzekeringen 2004.
16. Romano PS, Waitzman NJ, Scheffler RM, Pi RD. Folic acid fortification of grain: an economic analysis. Am J Public Health 1995;85:667-76.
17. Wisselkoers, De Nederlandsche Bank, (http://www.statistics.dnb.nl) (20 October 2006, date accessed).
18. World Health Organisation. http://www3.who.int/whosis/country/ (3 November 2006, date accessed).
19. Rodenburg-Van Dieten. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie (Dutch guidelines for pharmacoeconomic research; evaluation and actualisation) 27 October, 2005, Publication number FARM 24088606, http://www.cvz.nl/resources/rpt0510_richtlijnen_FEO_tcm28-17860.pdf (23 November 2006, date accessed).
20. Postma MJ, Londeman J, Veenstra M, De Walle HEK, et al. Cost-effectiveness of periconceptional supplementation of folic acid. Pharm World Sci 2002;24:8-11.
21. 12 intake an d cognitive decline among community-dwelling older persons. Arch Neurol 2005;62:641-5.
22. Hirsch S, De la Mazza P, Barrera G, et al. The Chilean flour folic acid fortification program reduces serum homocysteine levels and masks vitamin b-12 deficiency in elderly people. J Nutr 2002;132:289-91.
23. Flood VM, Webb KL, Smith W, et al. Original communication, folate fortification: potential impact on folate intake in an older population. Eur J Nutr 2001;55:793-800.
24. Schneider JA, Tangney CC, Morris MC. Folic acid and cognition in older persons. Expert opinion on drug safety 2006;5:511-22.
25. Verhoef P, Katan MB. Onzekere effecten van foliumzuur op andere aandoeningen dan neuraalbuisdefecten (Uncertain effects of folic acid for other abnormalities than neural tube defects). Nederlands Tijdschrift voor Geneeskunde 2006;150:1439-42.
26. Durga J, Verhoef P, Anteunis LJC, et al. Effects of folic acid supplementation on hearing in older adults. Ann Intern Med 2007;146:1-9.
27. Scarano MI, Strazzullo M, Matarzzo MR, D'esposito M. DNA Methylation 40 years later: its role in human health and disease. J Cell Physiol 2005;204:21-35.
28. Stevens VL, Rodriguez C, Pavluck AL, et al. Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol 2006;163:989-96.
29. Sanjoaquin MA, Allen N, Couto E, et al. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 2005;113:825-8.
30. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. Br Med J 2006;333:1114-7.
31. American Heart Association. Folic acid fortification may have lowered stroke deaths. 2004, http://www.americanheart.org/presenter.jhtml? identifier_3019554 (20 November 2006, date accessed).
32. Yang Q, Botto LD, Erickson JK, et al. Improvement in stroke mortality in Canada and the United States, 1990-2002. Circulation 2006;113:1335-43.
33. De Walle HEK, Reefhuis J, Cornel MC. Folic acid prevents more than neural tube defects: a registry-based study in the northern Netherlands. Eur J Epidemiol 2003;18:279-80.
34. Botto LD, Mulinare J, Erickson JD. Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps. Am J Med Genet 2003;121A:95-101.
35. Hashmi SS, Waller DK, Langiois P, et al. Prevalence of nonsyndromic oral clefts in Texas: 1995-1999. Am J Med Genet 2005;134A:368-72.
36. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases, a meta-analysis of randomized controlled trials. JAMA 2006;296:2720-6.
37. Clarke RJ. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282-7.
38. Scientific Advisory Committee on Nutrition, Folate and Disease Prevention, TSO London, 2006, ISBN 978 0 11 243111 4.
39. Food Safety Authority of Ireland, Report of the National Committee on folic acid food fortification, 2006, ISBN 1-9004465-43-9.